Wellington Management Group LLP Buys 1,724,588 Shares of Roivant Sciences Ltd. $ROIV

Wellington Management Group LLP lifted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 179.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,687,870 shares of the company’s stock after buying an additional 1,724,588 shares during the period. Wellington Management Group LLP’s holdings in Roivant Sciences were worth $95,124,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of ROIV. Morgan Stanley grew its position in Roivant Sciences by 31.7% in the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after acquiring an additional 14,036,696 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Roivant Sciences by 365.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after acquiring an additional 8,621,567 shares during the period. Norges Bank bought a new position in shares of Roivant Sciences during the fourth quarter valued at $112,750,000. Jefferies Financial Group Inc. acquired a new stake in shares of Roivant Sciences in the 4th quarter valued at $76,272,000. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of Roivant Sciences by 47.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 10,677,894 shares of the company’s stock valued at $231,710,000 after purchasing an additional 3,445,511 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $35.77, for a total value of $7,154,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,599,154 shares of the company’s stock, valued at approximately $57,201,738.58. The trade was a 11.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Melissa B. Epperly sold 17,750 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.38, for a total transaction of $610,245.00. Following the transaction, the director owned 16,474 shares in the company, valued at $566,376.12. The trade was a 51.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,055,913 shares of company stock worth $107,261,258 in the last quarter. Insiders own 8.80% of the company’s stock.

Roivant Sciences Stock Performance

Roivant Sciences stock opened at $34.52 on Wednesday. The business’s fifty day moving average is $35.27 and its two-hundred day moving average is $31.04. The firm has a market cap of $24.93 billion, a P/E ratio of -65.13 and a beta of 1.12. Roivant Sciences Ltd. has a 52 week low of $11.94 and a 52 week high of $37.97.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The company had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. On average, equities research analysts predict that Roivant Sciences Ltd. will post -2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ROIV has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $41.00 target price on shares of Roivant Sciences in a report on Friday, August 28th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Tuesday, August 25th. Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Roivant Sciences in a research note on Wednesday, August 19th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Roivant Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $35.14.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.